EGFR Protein, Cynomolgus (HEK293, His)

EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways. EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity. EGFR Protein, Cynomolgus (HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-10*His labeled tag.

The EGFR protein, a receptor tyrosine kinase, binds ligands of the EGF family, including EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG, and HBEGF/heparin-binding EGF. This interaction initiates cascades that convert extracellular signals into cellular responses, involving receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2, activating downstream signaling cascades, including RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC, and STATs modules. Additionally, EGFR may trigger the NF-kappa-B signaling cascade and directly phosphorylate proteins like RGS16, activating its GTPase activity, and potentially linking EGF receptor signaling to G protein-coupled receptor signaling. Furthermore, EGFR phosphorylates MUC1, enhancing its interaction with SRC and CTNNB1/beta-catenin. It positively regulates cell migration through interaction with CCDC88A/GIV, retaining EGFR at the cell membrane post-ligand stimulation, thereby promoting EGFR signaling and triggering cell migration. Beyond its canonical functions, EGFR contributes to enhancing learning and memory performance and plays a role in mammalian pain signaling, with isoform 2 potentially acting as an antagonist to EGF action^{[1][2][3][4][5]}.

1.This product does not contain protein kinase domain.
2.Immobilized EGF Protein, Human, Recombinant (ECD, hFc Tag) at 2 μg/mL (100 μL/well) can bind EGFR Protein, Cynomolgus, Recombinant (ECD, His Tag), the EC₅₀ is 150-500 ng/mL.
3.Immobilized Anti-EGFR(MK)-IgG1 Antibody (Cetuximab) at 2 μg/mL (100 μL/well) can bind EGFR Protein, Cynomolgus, Recombinant (ECD, His Tag),the EC₅₀ is 2-8 ng/mL.
4.Immobilized Cynomolgus EGFR, at 2 μg/mL (100μL/well) can bind Human EGF. The ED₅₀ for this effect is 2-10 ng/mL.

• 
  Immobilized Cynomolgus EGFR, at 2 μg/mL (100μL/well) can bind Human EGF. The ED₅₀ for this effect is 4.983 ng/mL.

Cynomolgus

HEK293

C-10*His

XP_005549616 (L25-S645)

102138724  [NCBI]

Extracellular Domain

MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSEFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDTLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSSQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCQNVSRGRECVDKCNILEGEPREFVENSECIQCHPECLPQVMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCARNGPKIPS

Approximately 80-100 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

• 
  ≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

1.Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4, 5% trehalose,5% mannitol and 0.01% Tween 80.
2.Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4, 8% trehalose.
Please refer to the lot-specific COA for specific buffer information.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Kattaia AAA, et al. Epidermal growth factor attenuates lingual papillae lesions in a rat model of sialoadenectomy. Tissue Cell. 2020 Apr;63:101319.  [Content Brief]

  [2]. Puig S, et al. EGFR Signaling Causes Morphine Tolerance and Mechanical Sensitization in Rats. eNeuro. 2020 Apr 6;7(2):ENEURO.0460-18.2020.  [Content Brief]

  [3]. Kontić M, et al. Association between EGFR expression and clinical outcome of laryngeal HPV squamous cell carcinoma. Acta Otolaryngol. 2019 Oct;139(10):913-917.  [Content Brief]

  [4]. Norton CE, et al. Augmented Pulmonary Vasoconstrictor Reactivity after Chronic Hypoxia Requires Src Kinase and Epidermal Growth Factor Receptor Signaling. Am J Respir Cell Mol Biol. 2020 Jan;62(1):61-73.  [Content Brief]

  [5]. Maugeri G, et al. Protective effect of PACAP-38 on retinal pigmented epithelium in an in vitro and in vivo model of diabetic retinopathy through EGFR-dependent mechanism. Peptides. 2019 Sep;119:170108.  [Content Brief]